TULIP 1 - highlights from the ACR meeting - a podcast by BMJ Group

TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.

Further episodes of ARD podcast

Further podcasts by BMJ Group

Website of BMJ Group